ALK and non-small cell lung carcinoma: In particular, patients with epidermal growth factor receptor (EGFR) mutant NSCLC and anaplastic lymphoma kinase (ALK) rearranged NSCLC have access to small molecule tyrosine kinase inhibitors (TKIs) with better CNS response rates than most cytotoxic chemotherapies [6, 7, 8].